Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset A. Mangia , S. Fagiuoli , V. Di Marco , S. Shafran , M. Khalili , S. Milligan , G. Papatheodoridis , D. Ouzan , S. Rosati , A. Ramji , E. Teti , M. Garcia-Retortillo , F. Andres Perez Hernandez , A. Wong , C. Fraser , S. Rodriguez-Tajes , E. Jimeneiz Mutiloa , L. Enrique Morano Amado , J. O'Loan , F. Campanale , G. Macedo , M. Milella , C. Brixko , M. Buti , M. Guerra Veloz , Roberto Ranieri , S. Borgia , A. Bascia , C. M. Fern Rodriguez , B. Conway , V. de Ledinghen , M. Fenech , P. Ryan , I. Maida , A. Martins , S. Scherbakovsky , I. Ntalla , C. Hernandez , K. Vanstraelen , J. Turnes JOURNAL OF HEPATOLOGY（2023）
摘要
Background and Aims More HCV-patients (pts) being started on direct-acting antivirals (DAAs) are belonging to vulnerable populations. This real-world analysis describes the profiles of these populations.
更多 查看译文
关键词
hcv, patient profiles, sofosbuvir/velpatasvir, real-world
AI 理解论文
溯源树
样例
